DongBao东宝品牌怎么样 申请店铺

我要投票 DongBao东宝在中草药行业中的票数:571 更新时间:2025-11-22
DongBao东宝是哪个国家的品牌?「DongBao东宝」是 通化东宝药业股份有限公司 旗下著名品牌。该品牌发源于吉,由创始人李一奎在1997-09-12期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力DongBao东宝品牌出海!将品牌入驻外推网,定制DongBao东宝品牌推广信息,可以显著提高DongBao东宝产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

DongBao东宝怎么样

通化东宝集团有限公司坐落于中国著名的“医药城”吉林省通化市西郊,集自然美丽风光、历史人文景观、民族医药宝库为一体的兴办企业最佳之地。

1984年,年仅32岁的青年企业家李一奎以他超人的胆识和非凡的魄力,创建了白山滋补品厂。

1992年12月,组建了中国通化东宝集团。其间先后兼并了数家企业,特别是在1992年兼并了集团所在地通化县二密镇恒德村,在国内首创“以企兼农”典型范例,在全国引起强烈反响。集团成立13年来,企业规模发展之猛,多元化项目经营之广,兼并国营民企数量之多,生产设备与工艺流程之先,科研队伍研究水平之高,都堪称国内企业发展之奇迹,被业内人士誉为“东宝模式”,创造了中国企业快速蓬勃发展的神话。

东宝的制药业,以拥有世界上最先进的生物制药尖端技术而备受世人瞩目。先后研制推出了“镇脑宁”,东宝肝泰片、脑血康片等一大批国家级新药和拳头产品。在生物制药领域,集团先后投入数亿元科研经费,于1998年成功研制出具有中国独立知识产权的高科技制剂药品“甘舒霖”,填补了国内空白,使中国继美国、丹麦之后成为世界上第三个能生产基因重组人胰岛素、第二个能生产甘精胰岛素的国家,该成果被587名中国工程院院士评为中国十大科技进展新闻奖。目前,投资总额为3.5亿元的国家振兴东北老工业基地重点扶持项目——东宝基因重组人胰岛素二期扩建工程正在紧张引进和安装国外先进设备,在近两年内将达产3000公斤,满足日益增长的国内和国际市场需求。东宝集团已成为世界上具有相当规模、拥有当今先进技术的人胰岛素生产基地之一。

东宝集团坚持科学发展观,积极构建和谐型企业。1994年集团在扒宝沟建立了全国第一家由企业兴建的自然保护区;1995年先后投入600余万元,修筑507米长的堤坝和拦水坝;2003年初集团通过了国家ISO14001环境管理体系认证;使集团成为“山青、水碧、天蓝”山川秀美的生态型现代化企业,做到了经济效益与生态效益互利双赢。

今天的东宝集团,在全国人大代表、集团董事长李一奎先生的带领下,乘借国家振兴东北老工业基地的春风,励精图治,只争朝夕,为打造中国民族品牌,领跑世界生物制药技术而努力拼搏,阔步前进!

Tonghua Dongbao Group Co., Ltd. is located in the western suburb of Tonghua City, Jilin Province, a famous "medicine city" in China. It is the best place to set up an enterprise integrating natural beautiful scenery, historical and cultural landscape, and national medicine treasure house. In 1984, Li Yikui, a 32-year-old young entrepreneur, founded Baishan tonic factory with his superhuman courage and extraordinary courage. In December 1992, China Tonghua Dongbao group was established. During this period, several enterprises were merged successively, especially Hengde village, Ermi Town, Tonghua County, where the group is located in 1992. It is the first typical example of "combining enterprise with agriculture" in China, which has aroused strong repercussions all over the country. In the past 13 years since the establishment of the group, the rapid development of the enterprise scale, the wide diversification of project management, the large number of state-owned private enterprises to be merged, the first production equipment and technological process, and the high research level of scientific research team have all been regarded as the miracle of the development of domestic enterprises, known as the "Oriental model" by the insiders, and created the myth of the rapid and vigorous development of Chinese enterprises. Dongbao's pharmaceutical industry, with the most advanced biopharmaceutical technology in the world, has attracted worldwide attention. A large number of state-level new drugs and blockbuster products, such as "zhennaoning", Dongbao Gantai tablet, Naoxuekang tablet, have been developed and launched successively. In the field of biopharmaceutical, the group has successively invested hundreds of millions of yuan in scientific research funds. In 1998, the group successfully developed "gansulin", a high-tech pharmaceutical preparation with independent intellectual property rights in China, which filled in the domestic gap. After the United States and Denmark, China has become the third country in the world that can produce recombinant human insulin and the second country that can produce insulin glargine. This achievement has been ranked 587 in China Academicians of the Chinese Academy of Engineering awarded the top ten science and technology progress News Awards. At present, the second phase expansion project of Dongbao gene recombinant human insulin, a key supporting project for revitalizing the old industrial base in Northeast China with a total investment of 350 million yuan, is urgently introducing and installing foreign advanced equipment, which will reach a production capacity of 3000 kg in recent two years, meeting the growing domestic and international market demand. Dongbao group has become one of the human insulin production bases with considerable scale and advanced technology in the world. Dongbao group adheres to the scientific concept of development and actively constructs a harmonious enterprise. In 1994, the group established the first enterprise built Nature Reserve in babaogou; in 1995, it invested more than 6 million yuan to build 507 meter long dams and dams; at the beginning of 2003, the group passed the national ISO14001 environmental management system certification; the group became an ecological modern enterprise with beautiful mountains and rivers, achieving economic and ecological benefits Mutual benefit and win-win situation. Today's Dongbao group, under the leadership of Mr. Li Yikui, deputy to the National People's Congress and chairman of the group, takes advantage of the spring breeze of the country's revitalization of the old industrial base in Northeast China, makes every effort to build a Chinese national brand and lead the world's biopharmaceutical technology, and makes great progress!

本文链接: https://brand.waitui.com/f89fb8898.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

报告:“成分党”成为美妆主流消费群体

毕马威近日发布的《"颜"值经济新篇章:2025年中国美妆市场行业报告》(以下简称《报告》)显示,据调查,58.8%的消费者将产品成分作为购买决策的首要考量因素,“成分党”成为主流消费群体。与此同时,300-500元中端价格带产品市场份额显著提升,而超低价与高端市场则双双承压,反映出消费者在追求"悦己"体验的同时,更加注重产品的实际功效与性价比。(新浪财经)

4分钟前

美联储传声筒:鲍威尔不是降息的最大障碍 美联储内部共识机制濒临瓦解

“美联储传声筒”Nick Timiraos撰文称,特朗普本周表示,他预计在明年5月任命新的美联储主席后,利率将大幅下降。然而,美联储内部反对12月降息声浪越来越大,这意味着他的愿望可能难以实现。无论鲍威尔在12月选择按兵不动还是降息,他都面临近八年任期内最严重的内部阻力。这种分歧可能延续至明年,这意味着,即便更换主席,也并不等于就能确保会有更多降息。一些人担忧,若特朗普无法如愿以偿,可能会采取更激进手段削弱央行独立性,以换取降息。(金十数据APP)

4分钟前

第八届进博会,上海合作交流采购团达成意向采购额7.12亿元

11月21日下午,第八届中国国际进口博览会上海市合作交流采购团总结展示交流活动在闵行区虹桥品汇成功举办。据介绍,本届进博会上海市合作交流采购团采购成交再创新高,共达成意向采购额7.12亿元人民币,比上届提升4.71%,累计意向采购额突破30亿元。采购团规模也进一步扩大,分团总数增至33家,共组织30批次、近760人次走进进博会参观交流,参与企业数量创历年新高。(界面新闻)

4分钟前

《哪吒2》不参加奥斯卡竞逐

当地时间11月21日,奥斯卡奖的主办方美国电影艺术与科学学院公布了符合资格参与最佳纪录长片、最佳国际影片以及最佳动画长片三个奖项竞逐的影片大名单。在最佳动画长片领域,今年有35部影片有资格“冲奥”,意外的是,《哪吒之魔童闹海》并不在其中。另一方面,《罗小黑战记2》榜上有名。(澎湃新闻)

4分钟前

IDEA研究院孵化企业视启未来获近亿元融资

36氪获悉,孵化自IDEA研究院的视觉大模型企业,视启未来(深圳)科技有限公司宣布完成近亿元天使轮融资。本轮由A股上市公司安凯微领投,昊辰资本、德虎资本、元禾璞华、银杏谷资本、力合中科、数字未来、九安智能等机构跟投。

4分钟前

本页详细列出关于DongBao东宝的品牌信息,含品牌所属公司介绍,DongBao东宝所处行业的品牌地位及优势。
咨询